CIK 0001840425
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
OSR Health, Inc.
Sign in to watch- Tickers
- OSRH OSRHW
- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 845052822
- Phone
- +1 425-635-7700
- Business address
- 10900 NE 4TH STREET, SUITE 2300, BELLEVUE, WA, 98004
- Former names
- OSR Holdings, Inc., Bellevue Life Sciences Acquisition Corp.
Securities
- OSRH Common stock OTC
- OSRHW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-29 | Hwang Kuk Hyoun Chairman & Chief Executive Off | Grant or award | +1,173,697 | $0.23 | $267K | 1,173,697 |
| 2026-10-29 | Kim Yeiseok Chief Operating Officer | Grant or award | +293,422 | $0.23 | $67K | 318,121 |
| 2026-10-29 | Bang Gihyoun Chief Financial Officer | Grant or award | +440,137 | $0.23 | $100K | 440,137 |
| 2026-10-29 | Cho Joong Myung Director | Grant or award | +120,000 | 120,000 | ||
| 2026-10-29 | Barberis Alcide Director | Grant or award | +120,000 | 120,000 | ||
| 2026-10-29 | Mah Seng Chin Director | Grant or award | +120,000 | 120,000 | ||
| 2025-02-14 | Bellevue Global Life Science Investors LLC 10% owner | Other acquisition | +43,000 | 2,043,500 | ||
| 2025-02-14 | Hwang Kuk Hyoun President and CEO | Other acquisition | +43,000 | 2,043,500 | ||
| 2025-02-14 | Hwang Kuk Hyoun President and CEO | Other acquisition | +7,531,634 | 9,575,134 | ||
| 2025-02-14 | Hwang Kuk Hyoun President and CEO | Other acquisition | +3,123,970 | 12,699,104 | ||
| 2023-03-23 | Hwang Kuk Hyoun Chief Executive Officer | Other disposition | −20,000 | 2,000,500 | ||
| 2023-03-23 | Hwang Kuk Hyoun Chief Executive Officer | Other disposition · Warrant for Common Stock | −20,000 | 370,000 | ||
| 2023-03-23 | Yoo David Jin Chief Financial Officer | Grant or award | +20,000 | 20,000 | ||
| 2023-03-23 | Yoo David Jin Chief Financial Officer | Grant or award · Warrant for Common Stock | +20,000 | 20,000 | ||
| 2023-03-23 | Bellevue Global Life Science Investors LLC 10% owner | Other disposition | −20,000 | 2,000,500 | ||
| 2023-03-23 | Bellevue Global Life Science Investors LLC 10% owner | Other disposition · Warrant for Common Stock | −20,000 | 370,000 | ||
| 2023-02-21 | Hwang Kuk Hyoun Chief Executive Officer | Other acquisition | +225,000 | 2,025,000 | ||
| 2023-02-21 | Hwang Kuk Hyoun Chief Executive Officer | Other disposition | −4,500 | 2,020,500 | ||
| 2023-02-21 | Bellevue Global Life Science Investors LLC 10% owner | Other acquisition | +225,000 | 2,025,000 | ||
| 2023-02-21 | Bellevue Global Life Science Investors LLC 10% owner | Other disposition | −4,500 | 2,020,500 |
Page 1 of 3 · 49 trades